PFIZER IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
No source documents are stored for PFIZER yet.
order filings · annual reports · concalls · ratings| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| ZYDUSLIFEZydus Lifesciences Ltd. | UNSTATED | 24,434 | 15,963–24,434 | — | — | FY26 | EST | 70% |
| “Zydus Hospira Oncology Pvt. Ltd. Zydus Hospira Oncology Pvt. Ltd. is a 50:50 contract manufacturing JV between the Company and Hospira Inc., USA (now part of P…” AR · +1 DOC | ||||||||
| AUROPHARMAAurobindo Pharma Ltd. | UNSTATED | — | — | — | R&D | FY26 | EST | 75% |
| “I further report that in the Secretarial Audit Report for the year ended March 31, 2024, it was reported that during 2008-09, the Company in the ordinary cours…” AR · +1 DOC | ||||||||
| POONAWALLAPoonawalla Fincorp Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “He previously served as Managing Director of Pfizer Limited and Non-Executive Chairman of Union Bank of India.” AR p.18 · 31-MAR-26 · +1 DOC | ||||||||
| PPLPHARMAPiramal Pharma Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “He was a member of Pfizer’s Global Manufacturing Leadership Team with responsibilities for global procurement, global external supply and a portfolio of Pfizer…” AR · +1 DOC | ||||||||
No order filings, annual reports, concalls or rating rationales are linked to PFIZER.
relationship sources are linked on ingest| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| SUPP MOM 1M | +4.4% | 14-NOV-26 | from 15-OCT-26 · Zydus Lifesciences Ltd. +4.4% w 1 · Poonawalla Fincorp Ltd. +9.9% w 0 · Piramal Pharma Ltd. +25.8% w 0 |